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In Brief
The establishment of a bacteriophage
genome-engineering platform and the
creation of synthetic phages with tunable
host ranges open the door for building
synthetic phage cocktails based on
common viral scaffolds. This approach
was used to enact efficient killing of
targeted bacteria and edit multi-species
communities and thus enables new
technologies for treating infectious
diseases and modulating microbial
consortia.
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Bacteria are central to human health and disease,
but existing tools to edit microbial consortia are
limited. For example, broad-spectrum antibiotics
are unable to precisely manipulate bacterial com-
munities. Bacteriophages can provide highly specific
targeting of bacteria, but assembling well-defined
phage cocktails solely with natural phages can be a
time-, labor- and cost-intensive process. Here, we
present a synthetic biology strategy to modulate
phage host ranges by engineering phage genomes
in Saccharomyces cerevisiae. We used this technol-
ogy to redirect Escherichia coli phage scaffolds to
target pathogenic Yersinia and Klebsiella bacteria,
and conversely, Klebsiella phage scaffolds to target
E. coli by modular swapping of phage tail compo-
nents. The synthetic phages achieved efficient killing
of their new target bacteria and were used to selec-
tively remove bacteria from multi-species bacterial
communities with cocktails based on common viral
scaffolds. We envision this approach accelerating
phage biology studies and enabling new technolo-
gies for bacterial population editing.
INTRODUCTION
Bacteriophages (phages) are natural biological nanomachines
that have evolved to infect host bacteria with exquisite specificity
and efficacy. Phages constitute the most abundant type of bio-
logical particles on Earth (Hendrix, 2003) and reproduce at the
expense of their host bacteria. Thus, phages have been explored
as a means of controlling pathogenic bacteria (d’Herelle, 1931),
but a poor understanding of themolecular relationships between
bacteria and their phages can lead to highly variable treatment
outcomes (Bru¨ssow, 2012; Lu and Koeris, 2011). With the rise
of drug-resistant bacterial infections and the sharp decline in
antibiotic discovery and development (Fischbach and Walsh,
2009), phage therapy is regaining attention after years of
declining interest (Carlton, 1999; Lu and Collins, 2007, 2009).
Furthermore, despite the important role that microbial popula-
tions play in regulating human health and disease (Grice and
Segre, 2012), strategies for precisely manipulating complex mi-Cellcrobial communities are lacking. With their ability to kill or deliver
DNA into specific bacteria, phages constitute a promising plat-
form for editing microbial populations (Bikard et al., 2014; Citorik
et al., 2014). However, the limited host range of most naturally
isolated phages means that phage cocktails are often needed
to address real-world applications (Sulakvelidze et al., 2001),
but the high diversity of natural phages poses a challenge for
the engineering, manufacturing, and regulatory approval of
phage products. Thus, enhancing the range of targetable bacte-
ria by adding natural phages to cocktails is counterbalanced
with the challenge of producing and testing well-defined multi-
component mixtures for regulatory approval.
Creating phage-based therapeutics and diagnostics is also
limited by the difficulty of engineering phages. Lytic phage
DNA is often too large for in vitro manipulation and does not
reside for very long inside of bacteria, making it difficult to modify
phage genomes during their reproductive cycle. Phage genome
engineering is classically carried out with allele replacement
methods, whereby a piece of the phage genome is cloned
and manipulated in bacteria, which is then infected with the
phage, leading to homologous recombination of the modified
DNA segment into the phage genome. This process is inefficient,
because many phages degrade resident DNA upon entry, and
time consuming, due to the need to screen for recombinant
phages but the lack of phage selectable markers. Recently,
CRISPR-Cas systems have been used for counter-selection
against phage T7 and the heavily modified genomes of a few
members of the T-even family (Kiro et al., 2014; Martel and Moi-
neau, 2014; Yaung et al., 2014). We have used the Strepto-
coccus pyogenes CRISPR-Cas9 system to select for mutants
in phage T7 but with variable efficiencies (data not shown).
Furthermore, large stretches of phage DNA can encode prod-
ucts toxic to bacteria, thus preventing their manipulation within
bacterial hosts. Existing approaches are also limited in their
ability to simultaneously engineer multiple non-contiguous loci
in phage genomes. Here, we demonstrate a high-throughput
phage-engineering platform that leverages the tools of synthetic
biology to overcome these challenges and use this platform to
engineer phages with tunable host ranges for microbial popula-
tion editing.
RESULTS
Yeast Platform for Bacteriophage Genome Engineering
We used an efficient yeast-based platform (Jaschke et al., 2012;
Lu et al., 2013) to create phages with novel host ranges based onSystems 1, 187–196, September 23, 2015 ª2015 Elsevier Inc. 187
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Figure 1. Yeast Platform for Phage Engineering
(A) Schematic illustrating the workflow to capture and reboot phages using our yeast platform. An entire phage genome or all PCR products spanning an entire
phage genome are transformed into yeast cells, alongwith a linearized yeast replicon fragment from the yeast artificial chromosome, pRS415. In yeast, the phage
genome is assembled and captured in the YAC by gap repair cloning. The resultant YAC-phage DNA is extracted and transformed into host bacteria. Active
phages are produced from the YAC-phage DNA and generate plaques on a lawn of host bacteria.
(B) High-titer phage lysates (>109 PFU/ml) were spotted onto E. coli 10G lawns, which were sensitive only to T7 and T3 phages.
(C) Rebooting T7 and T3 phages from purified phage genomes (10 ng) after electroporation into 10G, recovery in LB, chloroform sterilization, and plating with
E. coli BL21.
(D) All tested phage genomes (10–200 ng), including non-E. coli phages, could be rebooted by electroporation into E. coli 10G cells and plating supernatants with
host bacteria. Host bacteria used to plaque rebooted phage genomes were IJ1668 K-12 hybrid; K1 capsule for K1E, K1F, and K1-5 phages, IJ612 Salmonella
typhimurium LT2 for SP6 phage, Pseudomonas aeruginosa PAO1 for LUZ19 phage, Pseudomonas putida C1S for gh-1 phage, and Klebsiella sp. 390 for K11
phage.
(E) An example of capturing and rebooting a phage through the yeast platform. An excised YAC pRS415 amplicon and the T7 genome were co-transformed in
yeast cells. The T7 genome was captured in the YAC by gap repair cloning in yeast. Progeny phages were produced from YAC-T7 DNA via E. coli 10G and
generated plaques on E. coli BL21.common viral scaffolds. Inspired by gap repair cloning in yeast
and the work of Gibson et al. (2008), we captured phage ge-
nomes into Saccharomyces cerevisiae, thus enabling facile
genetic manipulation of modified genomes that can be sub-
sequently reactivated or ‘‘rebooted’’ into functional phages after
transformation of genomic DNA into bacteria (Figure 1A). First,
the entirety of the viral genome to be assembled in yeast is ampli-
fied by PCR so that each adjacent fragment has homology over
R30 bp. The first and last fragments of the phage genome are
amplified with primers that carry ‘‘arms’’ that have homology
with a yeast artificial chromosome (YAC) fragment, which may
be obtained by PCR or any other suitable method. Upon trans-
formation of all viral genome fragments and the YAC into yeast,
gap repair joins each fragment to the adjacent one templated by
the homology regions at the end of each fragment, yielding a full
phage genome cloned into a replicative yeast plasmid. Yeast
transformants are then enzymatically disrupted to extract the188 Cell Systems 1, 187–196, September 23, 2015 ª2015 Elsevier InYAC-phage DNA, which is transformed into bacterial host cells
that can restart the viral life cycle. Plaques, if obtained, are
then picked, amplified, and sequenced to verify proper introduc-
tion of the desired mutations. If no plaques are obtained, it is still
possible to amplify parts of the YAC-phage genome from the
yeast clones to verify proper DNA assembly, to eliminate the
possibility of unwanted mutations, and to help determine poten-
tial reasons for the failure of the synthetic phage genome to pro-
duce viable offspring.
We confirmed that purified phage DNA from various phages
could be transformed into bacterial hosts to generate functional
phages. We targeted phages from the T7-family because their
lifecycle is largely host independent (Qimronetal., 2010) and there
is a relatively large number of family members for which genomic
sequences arepublicly available. These include coliphages T7 (40
kbp), T3 (38 kbp), K1E (K1-capsule-specific, 45 kbp), K1F (K1-
capsule-specific, 40 kbp), K1-5 (K1- or K5-capsule-specific, 44c.
AB
C Figure 2. Creation of Synthetic Phages with
Engineered Host Range
(A) We prepared multiple PCR fragments encoding
the wild-type T7 phage genome (T7WT) (PCR
fragments 1–4; 10.0, 10.0, 10.0, and 10.1 kbp,
respectively), T7 phage with the entire T3 phage
tail fiber (T7T3(gp17)) (PCR fragments 1–3 and 5–7;
10.0, 10.0, 10.0, 4.7, 1.7, and 3.7 kbp, respec-
tively), and T7 phage with a hybrid T7-T3 tail fiber
(T7T3(C-gp17)) (PCR fragments 1–3, 8, 9, and 7; 10.0,
10.0, 10.0, 5.2, 1.3, and 3.7 kbp, respectively). All
fragments were co-transformed and assembled in
yeast along with YAC DNA (3.0 kbp).
(B) Phage Awith its primary host determinant, gene
a, infects bacteria A, but cannot infect bacteria B.
Phage B with its primary host determinant, gene b,
infects bacteria B, but cannot infect bacteria A.
We hypothesized that swapping these host de-
terminants between phages would switch their
respective host ranges.
(C) Creation of synthetic T7 phage with phage 13a
tail fiber (encoded by gene 17). We synthesized
13a’s gene 17 and assembled it with the rest of the
T7 genome via overlapping PCR products in yeast
(PCR fragments 1–6 and YAC amplicon; 10.0, 10.0,
10.0, 4.8, 1.7, 3.7, and 3.0 kbp, respectively). The
YAC-phage DNA was extracted and used for
transformation.kbp), Salmonella phage SP6 (44 kbp), Pseudomonas phages
LUZ19 (44 kbp), gh-1 (37 kbp), and Klebsiella phage K11 (41
kbp). We used E. cloni 10G (10G) cells (Durfee et al., 2008) as a
one-time phage propagation host. Except for T7 and T3, all
phages used in this study (K1E, K1F, K1-5, SP6, LUZ19, gh-1,
and K11) cannot infect 10G (Figure 1B). Each purified phage
genome was electroporated into 10G directly. After incubation
and chloroform treatment, supernatants were mixed with over-
night cultures of each natural host bacteria for each phage in
soft agar, poured onto agar plates, and scored for plaque forma-
tion (Figures 1C and D). All the phages tested could be rebooted
from purified DNA into functional phages through one-step prop-
agation in 10G, even if their natural target species was not E. coli
(Figure 1D; Table S1).
Rebooting Bacteriophages from PCR Products via the
Yeast Platform
To determine whether phage genomes assembled in yeast can
be used to create viable phages, we first captured and rebooted
T7 (Figure 1E), T3, and LUZ19 phages. We used PCR to amplify
the YAC pRS415 and add arms homologous to the ends of the
phage genomes. We co-transformed the YAC amplicons with
phage genomic DNA into yeast. Confirmed YAC-phage DNA
was extracted from yeast and transformed into E. coli 10G.
These cells were then chloroform treated, and the lysates were
assessed for plaque-forming units (PFUs) on the natural bacterial
hosts of the phages (see Figure 1E for capturing and rebooting
T7). All three phage genomes yielded yeast clones that could
be rebooted to viable phages using this strategy.
Next, we successfully captured and rebooted eight different
phages that target E. coli, Salmonella, Pseudomonas, and Kleb-
siella (T7, T3, K1E, K1F, K1-5, SP6, gh-1, and K11) by assem-
bling overlapping 3.8- to 12-kbp-long PCR products spanningCellthe phage genomes with the linearized YAC in yeast (Figure 2A,
upper panel illustrates this process with T7 as an example; data
not shown for the others). These data demonstrate the efficient
assembly and instantiation of functional recombinant phages
via our yeast-engineering platform, which can potentially create
any desired genotype in one step from PCR products.
Swapping Tail Fibers Enables Modulation of Phage Host
Range
We explored the utility of our phage-engineering platform by
engineering the host range of phages. We first selected two
model phages, T7 and T3, which are well-known obligate lytic
phages that propagate on E. coli B (Demerec and Fano, 1945).
T7 and T3 have linear genomes that share high homology
with each other, in which the primary host determinant is the
product of gene 17 (gp17), the tail fiber (Dunn and Studier,
1983; Pajunen et al., 2002). Alterations in the gp17 sequence
have been linked to the recognition of different host receptors
and shifting host ranges (Molineux, 2006). Thus, we hypothesized
that exchanging gene 17 or fragments of gene 17between T7, T3,
and their relatives could be used to tune their host specificities
(Figure 2B). This is supported by previous data on naturally
occurring hybrids between T7 and T3, whose host range was
mostly dictated by which gp17 they harbored (Lin et al., 2012).
We examined the host range of T7 and T3 phage on diverse
bacterial panels that were differentially targeted by the two
phages. T3 is described as incapable of targetingmany common
lab E. coliK-12 strains (Molineux, 2006), sowe performed plaque
formation assays with four K-12 strains and a B strain (BL21)
as a control. As shown in Figure S1A, T7 plaqued efficiently
on all strains, while T3 did not produce plaques on BW25113
and MG1655 at a detectable frequency (Figure 3). T3 exhibited
3–4 orders-of-magnitude reductions in adsorption efficiencySystems 1, 187–196, September 23, 2015 ª2015 Elsevier Inc. 189
Figure 3. EOP of Natural, Reconstructed Wild-Type, and Synthetic Phages
EOP was determined with respect to a reference bacterium. Klebsiella sp. 390 was used as a reference for T7K11(gp11-12-17), K11, and K11WT. Y. ptb IP2666 was
used for T3R(gp17). For other phages, BL21 was used as the reference host. EOP data were log10 transformed and are presented as themean of three independent
experiments. Error bars represent SD. The ‘‘0’’ symbol indicates an EOP= 1, whichmarks the reference strain used for the EOP calculations within each phage. An
asterisk indicates that the EOP was below the detection limit (EOP < 108). Strain abbreviations are B, E. coli BL21; G, E. coli 10G; D, E. coli DH5a; W, E. coli
BW25113; M, E. coli MG1655; 4, E. coli ECOR4; 13, E. coli ECOR13; 16, E. coli ECOR16; K, Klebsiella sp. 390; I, Y. ptb IP2666; Y, Y. ptb YPIII; N, E. coli Nissle
1917.on BW25113 and MG1655 compared with the permissive BL21
strain (Figure S1B). Thus, we can differentiate between T7 and T3
using BW25113 or MG1655.
The gp17 tail fibers of T7 and T3 can be split in two domains.
The N-terminal 149 residues are thought to be necessary for the
tail fiber to bind to the rest of the capsid, while the remaining
C-terminal region forms a kinked shaft and harbors the recogni-
tion domain for host receptors at its tip (Steven et al., 1988).
The N-terminal regions of T7 and T3 share 99% identity at the
protein level, while the C termini exhibit 83% identity, with the
last 104 amino acids (aa) of the T3 protein showing only 62%
of identity to the corresponding 99 aa of the T7 protein. There-
fore, we hypothesized that swapping the C-terminal domain
between the two viruses would result in exchanging the host
ranges. We constructed synthetic phages, based on either the
T7 or T3 viral chassis, which carried engineered gene 17 alleles
composed of fragments from the other phage. Specifically, we
created six synthetic phages: T7 phage with the wild-type T7190 Cell Systems 1, 187–196, September 23, 2015 ª2015 Elsevier Intail fiber (T7WT), T7 phage with the C-terminal 410 aa region of
the T3 tail fiber (T7T3(C-gp17)), T7 phage with the entire T3 tail fiber
(T7T3(gp17)), T3 phage with the wild-type T3 tail fiber (T3WT), T3
phage with the C-terminal 405 aa region of the T7 tail fiber
(T3T7(C-gp17)), and T3 phage with the entire T7 tail fiber
(T3T7(gp17)). T7WT and T7 phages are the same at the genetic
level; however, T7WT phage was created by capturing the T7
genome in yeast and then rebooting this phage genome in bac-
teria and served as a control for the faithfulness of the recon-
struction process, whereas T7 was obtained from ATCC. The
same applies to T3WT and T3. Each phage was assembled in
yeast via four or six PCR fragments and was rebooted via trans-
formation into E. coli 10G (example schematics in Figure 2A). No
unexpected mutations were found in the heterologous gp17 re-
gions of the rebooted phages.
To examine the host specificities of our six engineered
phages, we performed plaque formation assays on a range of
E. coli, Klebsiella, and Yersinia pseudotuberculosis (Y. ptb)c.
A B
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Figure 4. Creation of Synthetic T3 Phage
with Yersinia Phage R Tail Fiber
(A) We introducedmutations in T3 gene 17 by PCR
to convert it into phage R gene 17 and assembled
the resultant product with the rest of the T3
genome and YACDNA in yeast (PCR products 1–6
and YAC amplicon; 10.0, 10.0, 10.0, 4.4, 0.2, 3.8,
and 3.0 kbp, respectively). The YAC-phage DNA
was extracted and used for transformation into
E. coli.
(B) Plaquing assay with T3WT and T3R(gp17) on
E. coli BL21, Y. ptb IP2666, and Y. ptb YPIII shows
that T3R(gp17) can infect both E. coli and Y. ptb. 10-
fold serial dilutions of phage lysates were spotted
on bacterial lawns and incubated for 4 hr at 37C
for E. coli BL21 or 24 hr at 30C for Y. ptb strains.
These pictures were cut out from Figure S2. The
bottom panels show images of individual plaques.
NP, no plaque.
(C) Killing curves of Y. ptb IP2666 treated with
T3R(gp17). 108 CFU/ml bacteria and 107 PFU/ml
phage were used (MOI 0.1). The data are pre-
sented as the mean of three independent experi-
ments. Error bars represent SD. Small error bars
are obscured by symbols. The detection limit was
2.0 3 103 CFU/ml.strains (Figures 3 and S2). T3T7(C-gp17) and T3T7(gp17) plaqued
on E. coli BW25113 and E. coli MG1655 at a similar EOP
as T7 and T7WT, while T3, T3WT, T7T3(C-gp17), and T7T3(gp17)
had >108-fold-reduced EOPs on these strains. In addition, T3,
T7T3(C-gp17), and T7T3(gp17) plaqued on E. coli ECOR16, while
T7, T3T7(C-gp17), and T3T7(gp17) did not. Furthermore, we also syn-
thesized a codon-optimized version of the tail fiber of the T7-like
coliphage 13a and created synthetic T7 phages containing the
entire 13a tail fiber (T713a(gp17)) or the C-terminal region of the
13a tail fiber (T713a(C-gp17)) (Figure 2C; Table S2). Although T7
and T7WT did not plaque on E. coli ECOR16, both T713a(gp17)
and T713a(C-gp17) were able to do so efficiently (Figures 3 and
S2). Thus, the C-terminal region of gp17 is a major host range
determinant, and new host ranges can be conferred onto T7-
like phage scaffolds by engineering tail fibers. Interestingly,
T713a(C-gp17) efficiently infected E. coli BW25113 and MG1655,
similar to T7 and T7WT, but T713a(gp17) did not, which suggests
that the N terminus of the phage 13a tail fiber can also alter infec-
tivity of the virus, although the mechanism is still to be investi-
gated (Figure 3). A second example of this phenomenon can
be found between T7T3(C-gp17) (Figures 3 and S2, lane 3) and
T7T3(gp17) (Figures 3 and S2, lane 4). While the former phage in-
fected Y. ptb YPIII (albeit with a low EOP), the latter phage and
wild-type T3 did not.
Coliphage T3 with a Yersinia Phage Tail Fiber Infects
both E. coli and Y. pseudotuberculosis
We further demonstrated that gene swapping between phages
can overcome species barriers by designing synthetic phage
based on T7 or T3 scaffolds that can infect bacteria other than
E. coli. We started with coliphage T3 and Yersinia phage R (38
kbp), since their gp17’s share 99.5% identity at the protein levelCelland differ by only three nucleotides in gene 17, suggesting these
could be responsible for their divergent host ranges. We intro-
duced these three mutations in T3 gene 17 by PCR so that it
would encode the same tail fiber as phage R (Figure 4A). While
T3 did not plaque on Y. ptb strains IP2666 and YPIII, which are
known hosts for phage R (Rashid et al., 2012), synthetic T3
phage with the R tail fiber (T3R(gp17)) was able to infect Y. ptb
IP2666 and YPIII (Figures 3 and S2). The adsorption efficiencies
of T3WT and T3R(gp17) against Y. ptb IP2666 were found to be
0.01% ± 0.01% and 90.05% ± 1.1%, respectively.
Interestingly, T3R(gp17) maintained the capacity to infect E. coli
BL21 (Figure 4B), demonstrating that the introduced mutations
conferred a host range expansion, and not just a host range shift.
In addition to plaquing assays, we further characterized the abil-
ity of T3WT versus T3R(gp17) to kill Y. ptb IP2666 over time. After
1.5 hr of treatment, T3R(gp17) killed 99.999% of IP2666, while
T3 had no effect on the bacteria (Figure 4C; Table S3A).
Redirection of Host Range between Coliphage and
Klebsiella Phage by Swapping Whole-Tail Components
We further overcame species barriers by engineering phages
with lower similarity with one another. K11 is a Klebsiella phage
that belongs to the T7-like family (Dietz et al., 1990). K11 shares
gene synteny with T7, but homology between K11 and T7 genes
is low, averaging only 59%among the genes that have homologs
between the two viruses. For comparison, T7 and T3 share 72%
identity at the genomic level between homologous genes. While
T7 is a coliphage and does not infectKlebsiella, K11 infectsKleb-
siella, such asKlebsiella sp. 390, but not E. coli (Figures 3 and S2)
(Bessler et al., 1973). Their respective host range determinants,
gp17, are very different and do not share any homology outside
of the N-terminal 150 amino acids, which is only 47% identicalSystems 1, 187–196, September 23, 2015 ª2015 Elsevier Inc. 191
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Figure 5. Creation of Synthetic T7 Phage
with Klebsiella Phage K11 Tail Compo-
nents as well as K11 Phage with T7 Tail
Components
(A) The tail complex of T7 phage is composed of
two components: a tubular structure and tail fibers.
The tubular structure consists of an upper do-
decameric ring made of adaptor protein gp11 and
a pyramidal hexameric complex of the nozzle
protein gp12. The tail fiber protein gp17 interacts
with the interface between gp11 and gp12 (Cuervo
et al., 2013). Schematics illustrate the construction
of synthetic hybrids between phages T7 and K11.
Whole genomes were amplified as overlapping
PCR amplicons. PCR fragments were co-trans-
formed and assembled in yeast (PCR fragments 1–
8 and YAC amplicon; 10.0, 10.0, 4.3, 3.0, 2.7, 4.8,
2.7, 3.7, and 3.0 kbp, respectively). YAC-phage
genomes were extracted and used for trans-
formation. We swapped K11 genes 11, 12, and 17
into T7 to create T7K11(gp11-12-17) and T7 genes 11,
12, and 17 into K11 to create K11T7(gp11-12-17).
(B) Plaquing of T7K11(gp11-12-17) and K11T7(gp11-12-17)
on E. coli BL21 and Klebsiella sp. 390. 10-fold
serial dilutions of phage lysates were spotted on
bacterial lawns and incubated for 4 hr at 37C.
These pictures were cut from Figure S3. The bottom panels show images of individual plaques. NP, no plaque.
(C) Killing curves of Klebsiella sp. 390 treated with T7K11(gp11-12-17).108 CFU/ml bacteria and107 PFU/ml phage were used (MOI0.1). The data are presented
as the mean of three independent experiments. Error bars represent SD. Small error bars are obscured by symbols. The detection limit was 2.0 3 103 CFU/ml.between the two proteins. Specifically, the T7 gp17 encodes tail
fibers, while the 322-aa-longer K11 gp17 directs the synthesis of
a tail spike, an enzymatic host range determinant that actively
breaks down the capsule of Klebsiella to allow the K11 phage
to gain access to unknown secondary receptors located
beneath the capsule (Bessler et al., 1973).
To create a T7 phage with a K11 tail fiber and a K11 phage with
a T7 tail fiber, we first swapped the entire gene 17, but this
yielded no viable phages. We then tried to construct composite
tail fibers composed of gene 17 fragments from both phages
hybridized at various points along the length of the gene, but
this was also unsuccessful at generating functional synthetic
phages. We speculated that one possible reason for these fail-
ures could be that the K11 genome cannot create productive
phages within E. coli 10G. However, the natural K11 genome
produced Klebsiella-infecting virions when it was rebooted via
10G cells (Figure 1D; Table S1).
Alternatively, the gene 17product fromK11may require a func-
tion or factor that is absent from T7. Cuervo et al., (2013) reported
that the tail of T7 phage, which assembles independently of the
head, is assembled from a dodecamer of gp11 (the adaptor)
and a hexamer of gp12 (the nozzle) (Figure 5A, upper), ontowhich
six trimers of gp17 attach. T7’s six tail fibers attach at the inter-
face between the adaptor and nozzle, thus making contacts
with both proteins. The adaptor ring is responsible for the attach-
ment of the preformed tail to the prohead via interactions with the
portal composed of 12 subunits of gp8. The homology between
the gp8 of T7 and K11 (80% identity at the amino acid level) is
much higher than the homology between the gp11 and gp12 pro-
teins of T7 and K11 (60 and 61% identity, respectively), which led
us to suspect that replacing all three tail genes of T7with their K11
equivalents (gp11, gp12, and gp17) could be necessary to create192 Cell Systems 1, 187–196, September 23, 2015 ª2015 Elsevier Infunctional virions (Figure 5A, lower). Indeed, both T7 with K11
tail components (T7K11(gp11-12-17)) and K11 with T7 tail compo-
nents (K11T7(gp11-12-17)) were successfully created and exhibited
tail-dependent host ranges. Specifically, T7K11(gp11-12-17) infected
Klebsiella sp. 390 and did not target E. coli, while K11T7(gp11-12-17)
infectedE. colibut did not plaque onKlebsiella (Figures 3, 5B, and
S2). The yeast-based phage engineering platform enabled the
facile construction of these phages via one-step genome con-
struction even though gene 11 and 12 are physically separated
from gene 17, a feat that would be difficult to achieve with other
phage engineering methods. To further validate the ability of
synthetic T7K11(gp11-12-17) to target Klebsiella, we performed a
time-course experiment that showed that T7K11(gp11-12-17) killed
99.955% of Klebsiella sp. 390 after 1 hr of treatment (Figure 5C;
Table S3B), but was about 100-fold less effective than K11WT
(Figures 5B and S3). Measured adsorption efficiencies of
T7K11(gp11-12-17) and K11WT against Klebsiella sp. 390 were
98% ± 2% and 92% ± 6% after 10 min, respectively, suggesting
that the reduced efficacy of T7K11(gp11-12-17) is not due to an
adsorption defect.
Synthetic Phage Cocktails Efficiently Remove Target
Bacteria from Mixed Bacterial Populations
Our results show that common phage scaffolds can be retar-
geted against new bacteria hosts by engineering single or multi-
ple tail components. This capability enables the construction of
defined phage cocktails that only differ in their host-range deter-
minants and can be used to edit the composition of microbial
consortia and/or treat bacterial infections. To demonstrate mi-
crobial population editing using synthetic phages derived
from T7 or T3 scaffolds but with differing host specificities, we
designed experiments to remove specific bacteria from mixedc.
Figure 6. Microbial Population Editing
Assay
A synthetic microbial community composed of
E. coli Nissle 1917, Klebsiella sp. 390, and Y. ptb
IP2666 was treated with various individual syn-
thetic phages and a pairwise combination of
phages. After adding 107 PFU/ml of each phage,
the resultant samples were incubated at 30C with
shaking for 1 hr. At each time point, bacteria were
collected, washed in saline, serially diluted, and
plated onto selective plates for viable cell counts
after a 24-hr incubation at 30C. The data are
presented as the mean of three independent ex-
periments, and the total numbers of cells (CFU/ml)
are shown. The sizes of the pie charts reflect the
total number of cells. Note that the chart does not
allow the display of fractions smaller than 1%.
The detailed data and the SD are shown in Table
S4A. The detection limit was 2.0 3 103 CFU/ml.populations containing Klebsiella sp. 390, Y. ptb IP2666, and
the probiotic E. coli strain Nissle 1917. The amount of each
bacterial member in this mixed population was quantified using
their differing sensitivities to chemical antimicrobials (Figure S4).
After a 1-hr treatment of the multi-species population with
T7K11(gp11-12-17) or T3R(gp17), >99.9% or >99% of their target bac-
teria, Klebsiella sp. 390 or Y. ptb IP2666, respectively, were
removed with no detectable impact on the remaining bacterial
species (Figure 6; Table S4A). Furthermore, a phage cocktail
consisting of two phages with the same chassis but different
host ranges, T7WT and T7K11(gp11-12-17), resulted in >99.9% killing
of Klebsiella sp. 390 and >99.9% killing of Y. ptb IP2666 after
1 hr, thus enriching for probiotic E. coli Nissle 1917 (Figure 6;
Table S4A).
We performed similar assays with a phage cocktail consisting
of two phages based on the T3 chassis (Figure S5). In this ex-
periment, we used a mixed bacterial population containing the
probiotic E. coli strain Nissle 1917, E. coli ECOR16 (sensitive to
T3WT), and Y. ptb IP2666 (sensitive to T3R(gp17)). After a 1-hr treat-
ment with a phage cocktail consisting of two phages with the
same T3 chassis but different host ranges, T3WT and T3R(gp17),
>99.9% E. coli ECOR16 and >98% Y. ptb IP2666 were killed
without affecting the remaining probiotic E. coli Nissle 1917 (Fig-
ure S6; Table S4B). These results demonstrate the high effi-
ciency and selectivity of our engineered phages in microbial
consortia and the potential of generating well-defined phage
cocktails and combining them with probiotics.
DISCUSSION
In this study, we utilized an efficient, yet simple, yeast-based
platform for phage engineering to modulate phage host ranges
for several members of the T7 phage family. Traditional phage
engineering strategies, such as in vitro manipulation, allele-ex-
change within bacterial hosts, and phage crossing via co-infec-Cell Systems 1, 187–196, Setion of bacteria (Beier et al., 1977; Garcia
et al., 2003; Lin et al., 2011) have been
used to modulate phage host range
(Pouillot et al., 2010; Te´tart et al., 1998;Trojet et al., 2011; Yoichi et al., 2005), but these strategies are
inefficient and unable to achieve multiple genetic modifications
in a single step. Screening for a desired mutation after classical
crossing or recombination experiments can require PCR, res-
triction digestion, or plaque hybridization on hundreds of indi-
vidual plaques, which are all costly and time-consuming
methods. Conversely, our strategy rarely requires the screening
of more than a few yeast clones, since we found that >25% of
yeast clones contained properly assembled phage genomes
(composed of up to 11 DNA fragments) that were bootable into
functional phages after transformation into bacteria. Previously,
a scheme for engineering phage T4 through electroporation of
PCR products was devised (Pouillot et al., 2010), but it is based
on a particular feature of the genetic regulation of T4 and cannot
easily be applied to other phage families. Recently, the 5.4-kb
filamentous coliphage fX174 was assembled in yeast in order
to stably store the genome and aid in phage refactoring (Jaschke
et al., 2012). In this approach, themajority of the genome assem-
bly was performed in vitro, and the YAC cloning wasmostly used
to store the resulting genome, whereas the majority of the
genome engineering in our approach stems from the actual
gap repair cloning process in yeast. In addition, the phages
we have cloned using this method are in the 38–45 kbp range,
and we have indications that they can also be used for much
larger phage genomes (e.g., up to 100 kbp; data not shown).
Leveraging yeast to modify phages enables the decoupling of
phage genome engineering from phage fitness and viability,
obviates the need for selective or screenable markers in phage
genomes, reduces the risks of phage contamination during the
engineering process, and permits facile one-step genetic manip-
ulations. For example, the ability to simultaneously engineer
multiple loci in a phage genome was crucial for constructing
T7K11(gp11-12-17) and K11T7(gp11-12-17).
However, a challenge of yeast-based phage engineering
(which is shared by in vitro engineering strategies) is the needptember 23, 2015 ª2015 Elsevier Inc. 193
to reboot modified phage genomes into functional phages. Here,
we used high-efficiency DNA transformation to deliver phage
DNA into bacterial hosts, but future work may be facilitated by
in vitro transcription-translation systems capable of supporting
functional phage synthesis (Shin et al., 2012). Another challenge
for the approach outlined here is identifying the loci that can be
manipulated to change phage host range. We anticipate that
the systematic construction of phage mutants will enable more
detailed mapping of host range determinants and potentially of
their bacterial targets. Phages, such as T7, T3, or R, initiate con-
tact with their hosts through their tail fibers encoded by gene 17
(Hu et al., 2013). On E. coli B strains, T3 recognizes the penulti-
mate glucose residue of the lipopolysaccharide (LPS), while T7
binds to an undetermined site further inward in the LPS (Moli-
neux, 2006). The exact receptor of phage R has not been deter-
mined but may be somewhere within the LPS of Y. ptb, since the
related phage phiA1122 has been shown to plaque efficiently on
strains of E. coli expressing the core LPS of Yersinia (Kiljunen
et al., 2011). The actual receptor bound by Klebsiella phage
K11 has not been formally documented but by analogy to phage
T7, we assumed that its gene 17 bore its host-determinant activ-
ity. Interestingly, K11’s gp17 is known to be a capsule depoly-
merase specific to the K11 capsule of Klebsiella (Bessler et al.,
1973) and we suspect that it is a tail spike because known Podo-
viridae that bind to and degrade capsules or smooth O-antigens
(e.g., K1F, SP6, P22, K1-5, and K1E) display tail spikes instead of
fibers.
In summary, we demonstrated that synthetic phages based on
common viral scaffolds can be designed to target a range of
different bacterial hosts. Furthermore, we showed that a cocktail
containing multiple engineered phages could effectively remove
select bacterial targets inmixedmicrobial populations.We antic-
ipate that the systematic and high-throughput engineering of
viral genomes will enable new applications for the editing of mi-
crobial communities and enhanced understanding of bacterial
viruses. For example, the engineering of common viral scaffolds
could help simplify the discovery and manufacturing of novel
bacteriophages and reduce the regulatory burden required for
the use of phage cocktails as human therapeutics. In future
work, we plan to expand our efforts to phages that are not rela-
tives of T3/T7 phages, and phages that target bacteria outside
of the Enterobacteriaceae family, including those which are ma-
jor members of the human gut microbiome (Cryan and Dinan,
2012; Gibson et al., 2014; Zeeuwen et al., 2013). Also, abundant
phage sequences contained within metagenomic databases
could be synthesized and booted into functional phage particles
for study and use. Finally, the systematic deconstruction and
manipulation of these viral nanomachines will enable a greater
understanding of phage biology and may provide insights that
are useful for bio-inspired nanotechnologies.
EXPERIMENTAL PROCEDURES
Strains, Vector, and Primers
Phages T7 (ATCC BAA-1025-B2, NC_001604) and T3 (ATCC 110303-B3,
AJ318471) were lab stocks. Phages K1E (NC_007637), K1F (NC_007456),
K1-5 (NC_008152), SP6 (NC_004831), and K11 (EU734173) were provided
by Ian Molineux (University of Texas, Austin). Phage LUZ19 (NC_010326)
was provided by Rob Lavigne (KU Leuven). Phage gh-1 (ATCC 12633-B1,
NC_004665) was obtained from ATCC. Synthetic phages are listed in Table194 Cell Systems 1, 187–196, September 23, 2015 ª2015 Elsevier InS5. S. cerevisiae BY4741 (MATa his3D1 leu2D0 met15D0 ura3D0) was ob-
tained from Thermo Scientific. E. coli strains BL21 (B, F ompT hsdSB (rB

mB
) gal dcm), DH5a (K-12, F l F80d lacZDM15 D(lacZYA-argF)U169
deoR recA1 endA1 hsdR17 (rK
 mK
+) phoA supE44 thi-1 gyrA96 relA1),
BW25113 (K-12, F l D(araD-araB)567 DlacZ4787(::rrnB-3) rph-1 D(rhaD-
rhaB)568 hsdR514), MG1655 (K-12, F l ilvG rfb-50 rph-1), and Nissle
1917 were obtained from lab stocks. E. cloni 10G (K-12, F l D(ara leu)
7697 araD139 DlacX74 galU galK F80d lacZDM15 recA1 endA1 nupG rpsL
(StrR) D(mrr-hsdRMS-mcrBC) tonA) from Lucigen is an E. coli DH10B deriva-
tive and is suitable for maintaining large DNA constructs (Durfee et al.,
2008). Bacterial strains IJ284 Klebsiella sp. 390 (O3:K11), IJ1668 K-12 hybrid;
K1 capsule and IJ612 Salmonella typhimurium LT2 were provided by Ian Mo-
lineux. Virulence-plasmid-less Y. pseudotuberculosis IP2666 and YPIII were
provided by JoanMecsas (Tufts University). P. aeruginosa PAO1was obtained
from a lab stock. E. coli libraries, such as the ECOR group and DECA set, were
sourced from the Thomas S. Whittam STEC Center (Michigan State Univer-
sity).P. putidaC1S (ATCC 23287) was obtained fromATCC. The pRS415 yeast
centromere vector with LEU2 marker (ATCC 87520) was obtained from a lab
stock. Primers used in this study are listed in Table S6.
Synthesis of Codon-Optimized 13a Gene 17
The gene was synthesized by Gen9 (Table S2).
Culture Conditions
S. cerevisiae BY4741 was cultured in YPD (1% Bacto Yeast Extract [BD], 2%
Bacto Peptone [BD], and 2% dextrose [VWR]) at 30C. Y. pseudotuberculosis
strains and P. putidaC1S were cultured in lysogeny broth (LB) (BD) at 30C. All
other strains were cultured in LB at 37C.
Preparation of Phage Genomes
Lysates weremade by infecting 200ml of logarithmically growing cells with the
appropriate phage at a MOI of 0.1–0.01 and incubating the cultures until clear-
ance. Cells were lysed, and lysates were sterilized by adding 200 ml chloroform
(Sigma). Lysateswere centrifuged at 8,000 g for 5min and then filtered through
0.22-mm filters (VWR) to remove cell debris. We added 216 ml of buffer L1
(20 mg/ml RNase A [Sigma], 6 mg/ml DNase I [NEB], 0.2 mg/ml BSA [NEB],
10 mM EDTA [Teknova], 100 mM Tris-HCl [VWR], and 300 mM NaCl [VWR]
[pH 7.5]) and incubated everything at 37C for 1 hr with gentle shaking. Then
we added 30 ml of ice-cold buffer L2 [30% polyethylene glycol [PEG] 6000
[Sigma], 3 M NaCl] and stored the samples overnight in 4C. Samples were
centrifuged at 10,000 g for 30 min at 4C. Phage pellets were suspended in
9 ml buffer L3 (100 mM Tris-HCl, 100 mM NaCl, and 25 mM EDTA [pH 7.5]).
Then we added 9 ml buffer L4 [4% SDS (VWR)] and incubated the samples
at 70C for 20 min. After cooling on ice, 9 ml of buffer L5 (2.55 M potassium
acetate [pH 4.8] [Teknova]) were added, and the samples were centrifuged
at 10,000 g for 30 min at 4C. Supernatants were passed onto QIAGEN-tip
100 system to extract DNA in accordancewith themanufacturer’s instructions.
Preparation of PCR Products for Assembling Phage Genomes
All PCR products were prepared with specific primer sets (Table S6) and KAPA
HiFi DNA Polymerase. Five to ten 3.8–12.0 kbp PCR products, including the
YAC, were used per reaction. Homology arms between the YAC and the phage
genomes were added to the first and last phage genome fragments or to the
YAC when capturing phage genomes from genomic DNA. The YAC amplicon
was gel extracted to reduce background.
Preparation of Yeast Competent Cells
S. cerevisiae BY4741 was grown in 5 ml YPD at 30C for 24 hr. Overnight cul-
tures were added into 50 ml of YPD, and incubated at 30C for 4 hr. Cells were
harvested by centrifugation at 3,000 g, washed with 25 ml water and then with
1 ml of 100 mM lithium acetate (LiAc) (Alfa Aesar), and suspended in 400 ml of
100 mM LiAc. 50 ml were used for each transformation.
Yeast Transformation
AllDNAsamplesanda linearizedpRS415were collected ina tube (0.5–4.0mg for
eachDNA sample and 100 ng linearized pRS415 in 50 ml water), andmixedwith
the transformation mixture (50 ml yeast competent cell, 240 ml 50% PEG3350
[Sigma], 36 ml 1 M LiAc, 25 ml 2 mg/ml salmon spermDNA [Sigma]). Themixturec.
was incubated at 30C for 30min, then at 42C for 20min or at 42C for 45min,
centrifuged at 8,000 g for 15 s, and suspended in 200 ml water. Transformants
were selected on complete synthetic defined medium without leucine (SD-
Leu) (0.67% YNB+Nitrogen [Sunrise Science Products], 0.069% CSM-Leu
[Sunrise Science Products], 2% dextrose) agar plates at 30C for 3 days.
Extraction of Captured Phage Genomes
Individual yeast transformants were picked into SD-Leu liquid medium and
incubated at 30C for 24 hr. DNA was extracted from these cells using the
YeaStar Genomic DNA Kit (Zymo Research) or Yeast Genomic DNA Purifica-
tion Kit (Amresco) in accordance with the manufacturer’s instructions.
Rebooting of Phages
An E. coli 10G strain was used as a host bacterium for the initial propagation of
phages. To reboot T7 and T3 phages, 3 ml of extracted DNA were electropo-
rated into 20–25 ml of cells in a 2-mm gap electroporation cuvette (Molecular
BioProducts) at 2,500 V, 25 mF, and 200 U using a Gene Pulser Xcell (Bio-
Rad). Cells were mixed with 3 ml of LB soft agar (LB + 0.6% agar) warmed
at 55C, poured onto LB plate, and incubated for 4 hr at 37C. To reboot
other phages, after electroporation, cells were incubated at 37C for 1–2 hr
in 1 ml of LB medium. Then we added drops of chloroform to kill the cells
and release phages. After centrifugation at 12,000 g for 1 min, supernatants
were mixed with 300 ml of overnight cultures of host bacteria for the phages
and 3 ml of LB soft agar, poured onto LB plate, and incubated for 4–24 hr at
30C or 37C.
One-Time Phage Propagation Assays
Weelectroporated 10–200 ng of purified phage genomes into E. coli 10G. After
incubation for 1–2 hr, we added chloroform to kill the cells and release phages
thatmay have failed to lyse cells. Then supernatants weremixedwith overnight
cultures of each natural host bacteria for each phage in soft agar, poured onto
agar plates, incubated for 4–24 hr at 30 to 37C, and analyzed for plaque
formation.
Determination of Plaque-Forming Units
Wemixed serially diluted phages in 0.95% saline, 300 ml of overnight culture of
host bacteria, and 3 ml of LB soft agar, and poured the mixture onto LB plates.
After 4–24 hr incubation at 30C or 37C, phage plaques were counted and
PFU/ml values were calculated.
Plaque Formation Assays
We mixed 300 ml of bacterial overnight cultures and 3 ml of LB soft agar and
poured the mixtures onto LB plate. After 5 min at room temperature (RT),
2.5 ml of 10-fold serially diluted phages in 0.95% saline were spotted onto
LB soft agar and incubated at 30C or 37C. Efficiency of plating (EOP) was
determined with respect to a reference bacterium for each phage. Klebsiella
sp. 390 was used as the EOP reference for T7K11(gp11-12-17), K11, and K11WT.
Y. ptb IP2666 was used for T3R(gp17). For other phages, BL21 was used as
the reference host.
Adsorption Assay
We mixed 100 ml of 108 CFU/ml target bacterial strains and phages (MOI =
0.5) and incubated everything at RT for 10 min. Then we added 700 ml of
0.95% saline and drops of chloroform to kill the cells and prevent the produc-
tion of progeny phages. After centrifugation at 11,000 g for 1min, supernatants
were serially diluted and mixed with 300 ml of overnight cultures of host bacte-
rial strains and 3 ml of LB soft agar, and the mixtures were poured onto LB
plates. After incubation, phage plaques were counted and adsorption effi-
ciencies were calculated according to the following equation:
Adsorption efficiencyð%Þ= ½1­ðPFU of unadsorbed phage=
original PFU in the host bacterium and phage mixtureÞ3 100:
Bacterial Killing Assays
Overnight cultures of Y. pseudotuberculosis IP2666 and Klebsiella sp. 390
were diluted 1:200 into LB and grown to log phase (108 CFU/ml), i.e., for
5 hr at 30C and for 3 hr at 37C, respectively. Bacterial cultures were mixedCellwith phage lysates (MOI 0.1) and incubated at 30C or 37C. At each time
point, bacteria were collected, washed twice with 0.95% saline, serially
diluted, plated onto LB, and incubated at 30C or 37C. Colonies were
enumerated to calculate CFU/ml.
Microbial Population Editing Assays
Overnight cultures of E. coli Nissle 1917, Y. pseudotuberculosis IP2666, and
Klebsiella sp. 390 or E. coli ECOR16 were diluted 1:200 into LB and grown
to log phase (108 CFU/ml), i.e., for 3 hr at 37C, for 5 hr at 30C, for 3 hr at
37C, and for 3 hr at 37C, respectively. Cultures were mixed and treated
with phage lysates (MOI0.1) and incubated at 30C. At each time point, bac-
teria were collected, washed twice with 0.95% saline, serially diluted, plated
onto LB, LB containing 25 mg/ml carbenicillin (VWR), and LB containing
1 mg/ml triclosan (VWR), and incubated at 30C. Colonies were enumerated
to calculate CFU/ml.
Statistical Analysis
For all data points in all experiments, three samples were collected. The data
are presented as themean, and the error bars represent the SD. In the subsec-
tions ‘‘Bacterial Killing Assays’’ and the ‘‘Microbial Population Editing Assays,’’
all CFU data were log10 transformed before analysis. EOPs were log10 trans-
formed before analysis (Figure 3).
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